BUZZ-Alector stock surges after agreement with Genentech on an experimental Parkinson's disease drug
路透社2026/10/05 11:54October 5 - The stock price of pharmaceutical company Alector (ALEC.O) surged by 44.20% in pre-market trading, reaching $2.61. The company has entered into a global licensing agreement with Genentech for AL050, an experimental drug developed by ALEC for the treatment of Parkinson's disease. ALEC has granted Genentech the exclusive worldwide rights to develop and commercialize AL050. According to ALEC, the agreement will bring an upfront payment of $100 million and may result in milestone payments of up to $1.17 billion by 2029. The company retains ownership of its ABC technology platform for developing therapies for neurodegenerative diseases, as well as all rights to use the platform in its research and development pipeline. As of the close of the previous trading day, ALEC's stock price had risen by 16.03%. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Due to possible errors in automation or lack of context, Reuters does not guarantee the accuracy of the automated translation, which is provided solely for the convenience of readers. Reuters assumes no responsibility for any damage or loss caused by the use of the automated translation.)
October 5 - ** Shares of pharmaceutical company Alector (ALEC.O) surged 44.20% in pre-market trading, reaching $2.61
** The company reached a global licensing agreement with Genentech for AL050, ALEC's experimental drug for treating Parkinson's disease
** ALEC granted Genentech exclusive global rights to develop and commercialize AL050
** According to ALEC, the agreement includes a $100 million upfront payment and the possibility of milestone payments up to $1.17 billion by 2029
** The company retains ownership of its ABC technology platform for developing therapies for neurodegenerative diseases, as well as all rights for its use in its research and development pipeline
** As of the close of trading on the previous day, ALEC shares were up 16.03%
(To facilitate non-English speakers, Reuters provides its reporting automatically translated into several other languages. Automated translations may contain errors or lack necessary context, and Reuters does not guarantee the accuracy of the automated translation. The automated translation is provided solely for the convenience of readers. Reuters accepts no responsibility for any damages or losses that may arise from the use of the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Indonesian Rupiah: Limited relief, challenging backdrop – OCBC
Buying Wind in the Cryptocurrency Market! Significant Activity in Bitcoin, Ethereum, and Solana! Here are the Details…
Hulamin says Paul Baloyi resigns as independent non-executive director
Hulamin said independent non-executive director Paul Baloyi resigned, effective Oct. 2, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hulamin Ltd. published the original content used to generate this news brief via SENS, the regulatory disclosure system operated by the Johannesburg Securities Exchange (JSE) (Ref. ID: S604350), on October 05, 2026, and is solely responsible for the information contained therein.
US Stock Move | Pneumococcal vaccine achieves late-stage clinical trial target, Vaxcyte (PCVX.US) opens more than 50% higher
On Monday, Vaxcyte (PCVX.US) soared more than 50% at the open and was up approximately 53% at the time of writing, with a market capitalization of 12.8 billions USD.
Crypto prices
More
